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ABSTRACT
Administration of small interfering RNAs (siRNAs)
leads to degradation of specific mRNAs utilizing
the cellular RNA interference (RNAi) machinery.
It has been demonstrated that co-administration of
siRNAs may lead to attenuation of activity of one of
the siRNAs. Utilizing antisense and siRNA-mediated
RNA-induced silencing complex (RISC) gene reduc-
tion we show that siRNA competition is correlated
with differences in the cellular expression levels
of Ago2, while levels of other RISC proteins have
no effect on competition. We also show that
under certain conditions siRNA competition rather
than reduction of cellular RISC levels may be
responsible for apparent reduction in siRNA
activity. Furthermore, exploiting siRNA competition,
we show that the RISC pathway loads and results in
detectable cleavage of the target RNA in  2h after
transfection. The RISC pathway is also capable of
being reloaded even in the absence of new protein
synthesis. RISC reloading and subsequent induction
of detectable cleavage of a new target RNA,
requires about 9–12h following the initial
transfection.
INTRODUCTION
RNAinterference(RNAi)isamechanismbywhichdouble-
stranded RNA triggers the inhibition of target gene
expression by inducing sequence-speciﬁc target mRNA
degradation (1). Short interfering RNAs (siRNAs), RNA
duplexes of 21–23 nucleotides, are important intermediates
in the RNAi pathway that lead to degradation of speciﬁc
mRNAs through the RNA-induced silencing complex
(RISC) (2). After cellular delivery of synthetic siRNAs,
the double-stranded molecules are incorporated into the
RISC-Loading Complex (RLC), which consists of the
RNase, Dicer and TRBP (the HIV trans-activating
response RNA-binding protein) (3). During assembly of
RISC, one of the two siRNA strands, referred to as the
passenger strand, is released, whereas the other strand
(guide strand) binds to the Argonaut protein Ago2 (4).
This strand then guides RISC to its complementary target
RNA,whichisﬁnallycleavedbytheRNaseactivitylocated
in the Ago2 protein, triggering its destruction (5–9).
It has been shown that inactive siRNAs can compete
with active siRNAs (10,11). Further, Koller et al. have
also reported that two ‘active’ siRNAs can compete with
each other; i.e. highly potent siRNAs are able to compete
with less potent siRNAs, limiting the ability of siRNAs
with lower potency to mediate mRNA degradation (12).
This observation may be particularly important as it
suggests that some component of the siRNA pathway is
present in cells in limiting quantities and some properties
of siRNA molecules must support discrimination between
potent and less potent siRNA duplexes.
The purpose of the current investigation is to begin
to dissect the molecular mechanisms by which siRNAs
are diﬀerentiated and the mechanisms supporting compe-
tition. We show that under certain conditions, siRNA
competition rather than reduction of cellular RISC levels
may be responsible for apparent reduction in siRNA
activity, suggesting that experiments in which siRNAs are
co-administered should be interpreted with caution in
order to distinguish the eﬀects of target reduction from
siRNA competition. We also show that siRNA competi-
tion, which varies signiﬁcantly between cell lines,
is correlated with diﬀerences in the expression levels of
Ago2. While cellular Ago2 levels aﬀect both siRNA
competition and potency, levels of other RISC-associated
proteins do not. Utilizing ASO and siRNA-mediated
reduction of RISC proteins we further demonstrate that
Ago2 appears to be a limiting component responsible,
at least in part, for siRNA competition. Finally, we exploit
the competition between siRNAs to better understand
the kinetic characteristics of RISC loading and reloading.
These results identify rate-limiting components for siRNA
activity in cultured cells.
MATERIALS AND METHODS
Preparation of antisense oligonucleotides andsiRNAs
Synthesis and puriﬁcation of phosphorothioate/20-MOE
oligonucleotides was performed using an Applied
*To whom correspondence should be addressed. Tel: 760 931 9200; Fax: 760 268 4989; Email: tvickers@isisph.com
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Biosystems 380B automated DNA synthesizer as
described previously (13). All ASOs were full phosphor-
othioate with 20-O-methoxyethyl substitutions at positions
1–5 and 16–20 (boldface type). Residues 5–15 are
unmodiﬁed 20-oligodeoxynucleotides, so they can serve as
substratesforRNaseH.ASOstargetedtoRISCgeneswere
identiﬁed following screening of 78 ASOs as previously
described (14). The sequences of the RNAse H ASOs are as
follows. Ago2 (NM_012154, RefSeq ID: EIF2C2): CTGC
TGGAATGTTTCCACTT (ISIS 136764); Dicer (NM_0
30621, RefSeq ID: DICER1): GCTGACCTTTTTGCT
TCTCA (ISIS 138648); TRBP (NM_004178, RefSeq
ID: TARBP2): TGCGGTGGGCTGGCCCAGAC (ISIS
237288); Exportin5 (NM_020750, RefSeq ID: XPO5):
GTTACCATTCTGTACAGGTA (ISIS 350560). Silencer
Pre-designed siRNAs for knockdown of RISC proteins
were obtained from Ambion (Austin, TX, USA). Ago2:
siRNA ID# 133832; Dicer: siRNA ID# 137011;
Exp5: siRNA ID# 109276; TRBP: siRNA ID# 139948.
PTEN (NM_000314, RefSeq ID: PTEN) and Eg5
(NM_004523,RefSeq ID:KIF11) synthetic unmodiﬁed
siRNAs were purchased from Dharmacon Research, Inc.
(Boulder, CO, USA). The sequence of the Eg5 siRNA is
CAACAAGGAUGAAGUCUAU (sense) and AUAGAC
UUCAUCCUUGUUG (antisense). The sequence of the
PTENsiRNAisAAGUAAGGACCAGAGACAA(sense)
and UUGUCUCUGGUCCUUACUU (antisense). The
sequence of the PTEN 40-mer ‘Dicer-substrate’ siRNA is
AAGUAAGGACCAGAGACAAAAA GGGAGUAACU
AUUCCCAG (sense) and CUGGGAAUAGUUACT
CCCUUUUUGUCUCUGGUCCUUACUUCC (anti-
sense). The sequence of the 19-mer is highlighted
within the 40-mer. A two-base overhang was added to
the antisense strand to ensure directionality of Dicer
cleavage.
siRNA/ASO treatment
Tissue culture medium, trypsin and Lipofectamine 2000
were purchased from Invitrogen (Carlsbad, CA, USA).
HeLa, T47D and U87-MG cells were obtained from the
American Type Tissue Collection (Manassas, VA, USA)
and cultured in DMEM supplemented with 10% fetal calf
serum, streptomycin (0.1mg/ml), and penicillin (100 units/
ml). Treatment of cells with siRNA and RNAse H ASOs
was performed using Opti-MEM media (Invitrogen)
containing 2–5mg/ml Lipofectamine 2000 and the indi-
cated amount of siRNA/ASO for 3–5h at 378C, as
described previously (14). For the generation of IC50
curves, cells were seeded in 96-well plates at 4000–6000
cells/well then treated at doses ranging from 2pM to
60nM in half-log serial dilutions 2–20nM siRNA
competitor (N=4–8/dose). Treated cells were incubated
overnight. The next day total RNA was puriﬁed from
96-well plates using an RNeasy 3000 BioRobot (Qiagen,
Valencia, CA, USA).
Reduction of target mRNA expression was determined
by qRT-PCR performed essentially as described elsewhere
(15). Brieﬂy, 200ng of total RNA was analyzed in a ﬁnal
volume of 50ml containing 200nM gene-speciﬁc PCR
primers, 0.2mM of each dNTP, 75nM ﬂuorescently
labeled oligonucleotide probe, 5ml RT-PCR buﬀer,
5mM MgCl2, 2U of Platinum Taq DNA Polymerase
(Invitrogen), and 8U of RNase inhibitor. Reverse tran-
scription was performed for 30min at 488C followed by
PCR: 40 thermal cycles of 30s at 948C and 1min at 608C
using an ABI Prism 7700 Sequence Detector (Applied
Biosystems). To avoid artifacts based upon well to well
variation in cell number, mRNA levels were normalized to
the total amount of RNA present in each reaction as
determined by Ribogreen assay (16) (Invitrogen). IC50
curves and P-values were generated using Prism 4 software
(GraphPad). Sigmoidal dose response was calculated
according to Y=Bottom+(Top Bottom)/(1+10)^
((LogEC50-X))); where X is the logarithm of concentration
and Y is the response. The sequence for the human Eg5
primer/probe set used in the RT-PCR reaction is GCC
CCAAATGTGAAAGCATT for the forward primer,
CTAAAGTGGGCTTTTTGTGAACTCT for the reverse
primer and CCTTTAAGAGGCCTAACTC for the probe.
The sequence for the human PTEN primer/probe set is
AATGGCTAAGTGAAGATGACAAT for the forward
primer,TGCACATATCATTACACCAG-TTCGTforthe
reverse primer and AGATGCCGTGTTTGATGGCTCC
AGC for the probe.
Primer probe sets used to analyze the levels of targeted
RISC genes are as follows. Human Ago2: CCAGCTACA
CTCAGACCAACAGA (forward primer), GAAAACGG
AGAATCTAATAAAATCAATGAC (reverse primer) and
CGTGACAGCCAGCATCGAACATGAGA (probe).
Human Dicer: ATT AACCTTTTGGTGTTTGATGAG
TGT (forward primer), GCGAGGACATGATGGAC
AAATT (reverse primer) and ATCTTGCAATC CTAGA
CCACCCCTATCGAGAA (probe). Human TRBP: CAG
CCCACCGCAAAGAAT (forward primer), TGCCACTC
CCAATCTCAATG (reverse primer), and CACCATGAC
CTGTCGAGTGGAGCGT(probe). HumanExp5:GCTG
TGAATATTCTCGGTTTGATTT (forward primer),
GGAAGCTAGTTTTGGGATCCAA (reverse primer)
and TCCTCCCGAGCACAACAAGG AGAGG (probe).
Westernblotting
Whole cell extracts were prepared by lysing cells in RIPA
buﬀer containing complete protease inhibitor mix
(Boehringer Mannheim). Protein concentration of the
cell extracts was measured by Bradford assay. Equal
amounts of protein (10–20mg) were resolved on a
NuPAGE Novex 8–16% Tris–glycine gel in Tris–Gly
SDS running buﬀer (Invitrogen Life Technologies) and
transferred to PVDF membranes (Invitrogen). The
membranes were blocked for 1h in PBS containing
0.05% Tween 20 (PBST) and 5% milk powder. After
overnight incubation at 48C with a 1/1000 dilution of a
mouse monoclonal antibody to Ago2, Exportin 5
(Abnova), Dicer [13D6] (Abcam), or a 1/3000 dilution of
a rabbit polyclonal antibody to TRBP (gift from J. Wu),
the membranes were washed in PBST and incubated with
a 1/5000 dilution of goat anti-rabbit or goat anti-mouse
HRP-conjugated antibody in blocking buﬀer. Membranes
were washed and developed using ECL detection system
(Amersham Biosciences). Subsequently, membranes were
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milk powder. After incubation at room temperature with a
1/5000 dilution of a mouse monoclonal tubulin antibody
(no. T-5168; Sigma-Aldrich), the membranes were washed
in PBST and incubated with a 1/5000 dilution of goat anti-
mouse HRP-conjugated antibody in blocking buﬀer and
developed as detailed above and exposed to ﬁlm (Kodak).
Bands were quantitated by densitometry and normalized
to the tubulin signal intensity.
Extracts of HeLa cells transfected with plasmids
expressing each of the analyzed proteins were also
evaluated by western analysis to prove the speciﬁcity of
each antibody and the molecular weight of the hybridized
product (Supplementary Figure 1). The plasmids expres-
sing Dicer and Exp5 under the control of the CMV
promoter were obtained from OriGene Technologies, Inc.
(Rockville, MD, USA). cDNAs for Ago2 and TRBP were
isolated from HeLa cell cDNA by PCR and cloned into
pcDNA3.1 (Invitrogen). For RISC gene overexpression
assays, 10mg of plasmid was introduced into cells at 50%
conﬂuence in 10cm dishes using SuperFect Reagent
(Qiagen). Following a 3h treatment, plasmid was removed
and fresh DMEM added to the cells, then incubated an
additional 24h prior to harvest and preparation of RIPA
extracts.
Apoptosisdetection
HeLa cells were seeded in 60mM dishes at 50%
conﬂuency. The next day cells were transfected with ISIS
138648 (anti-Dicer) at 30nM or a control ASO. Following
the transfection, cells were split and seeded in 96-well
plates at 5500 cells/well. Twenty-four hours later cells were
treated with 50nM PTEN 19- or 40-mer siRNA in the
presence of Lipofectamine 2000 as detailed above. One to
two days following the transfection, Caspase 3/7 levels
were determined using an Apo-ONE Homogeneous
Caspase-3/7 Assay kit (Promega) according to the
manufacturer’s protocol.
RISCprotein reduction and overexpression
For RISC reduction, HeLa cells were seeded in 10cm
dishes at 650000 cells per plate. The following day, RISC-
speciﬁc siRNA/ASO (above) was added at 50nM in Opti-
MEM media in the presence of 4mg/ml Lipofectamine
2000. Following a 4-h incubation, the transfection mixture
was aspirated and DMEM added to the cells. Following
an overnight incubation, cells were trypsinized, then
seeded in 96-well plates at 4000–6000 cells per well or
harvested for analysis of target RNA/protein reduction.
Cells in 96-well plates were allowed to adhere for 4h, then
siRNAs were added in the presence of Lipofectamine 2000
reagent as detailed above. For siRNA competition
experiments both siRNAs were pre-mixed then added
simultaneously to the cells (N=4/dose).
For RISC gene overexpression assays, 10mg of plasmid
was introduced into cells at 50% conﬂuence in 10-cm
dishes using SuperFect Reagent (Qiagen). Following a 3h
treatment, plasmid was removed and fresh DMEM added
to the cells. Following an overnight incubation, cells were
trypsinized then seeded in 96-well plates at 4000–6000 cells
per well for use in competition experiments or harvested
for analysis of target RNA/protein reduction.
Recombinant human Ago2 activity assay
One nanogram recombinant Ago2 (gift from J. Wu) was
incubated at 378C with 10nM of either PTEN 19-mer or
40-mer siRNA guide strand in cleavage buﬀer (10mM
Tris, pH 7.5, 100mM KCl, 2mM MgCl2, Protease
Inhibitor and 0.5mM DTT). After 2h, 0.1nM
32P labeled
target RNA was added. After 30min cleavage reactions
were quenched in gel loading buﬀer (Ambion, TX, USA).
Cleavage products were resolved by denaturing PAGE
and quantitated with Storm 850 Phosphorimager
(Molecular Dynamics).
Kinetic analysis of siRNA competition
To analyze kinetics of RISC loading, HeLa cells were
seeded in 96-well plates at 4500/well. The following day,
cells were transfected with 300pM Eg5 siRNA using Opti-
MEM media containing 4mg/ml Lipofectamine 2000.
The Eg5/Lipofectamine 2000 complex was removed at
timepoints between 0 and 240min from the initiation of
the transfection and replaced with a mixture of 300pM
Eg5 siRNA and 10nM PTEN siRNA (N=4/timepoint).
Cells were incubated 4h, then siRNA removed and fresh
DMEM added. Cells were incubated overnight then total
RNA was puriﬁed and Eg5 mRNA expression evaluated
by qRT/PCR.
For RISC reloading kinetics, HeLa cells were seeded
in 96-well plates at a density of 4000 cells/well. The
following day cells were transfected with 10nM
PTEN competitor siRNA in Opti-MEM media containing
3mg/ml Lipofectamine 2000. After 3h the PTEN siRNA/
Lipofectamine2000complexwasremoved,thecellswashed
with PBS, and fresh DMEM+5% FCS added. A 20nM
Eg5 siRNA complexed with 4mg/ml Lipofectamine 2000,
then 1/20 volume added directly to the pre-treated cells
(ﬁnal concentration=1nM). Immediately following the
PTEN siRNA pre-treatment and at intervals from 2–18h,
Eg5 siRNA was transfected at 300pM as detailed above
(N=8/timepoint). For each timepoint the siRNA/lipid
complex was removed after 3h, cells washed with PBS, and
fed with DMEM+10% FCS. Cells were incubated over-
night, then total RNA was puriﬁed and Eg5 mRNA
expression evaluated by qRT/PCR. Where indicated the
experiment was performed in the presence of 25mg/ml
cycloheximide (Sigma). Inhibition of protein synthesis was
conﬁrmed by measurement of cellular incorporation
35S-Translabel (MP Biomedicals).
For kinetic analysis of siRNA activity HeLa cells were
seeded in 96-well plates then treated with 10nM Eg5
siRNA as detailed above. Cells were harvested and total
RNA isolated beginning at 15min from the initiation of
transfection. The transfection mixture was removed from
cells at 4h for the 7 and 18h timepoints and complete
media added. Eg5 and PTEN mRNA expression was
assessed by qRT/PCR and normalized to total RNA as
measured by Ribogreen assay.
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Levels of RISC components andmagnitude of siRNA
competition vary between cell lines
Previous work has suggested that RISC components may
beratelimitingasco-transfectionoftwosiRNAsresultedin
loss of activity (11,12). In an attempt to correlate RISC
levels with observed diﬀerences in siRNA competition
and activity, the expression levels of Ago2, Dicer, TRBP,
and Exportin-5 (Exp5) were assessed by western blot
analysis in HeLa, T47D, U87-MG cells (Figure 1). The
ﬁgures below each set of duplicate lanes represent the
average normalized protein expression relative to HeLa
cells. While HeLa and U87-MG cells were found to have
similar levels of Dicer, levels were 3–5-fold higher in T47D
cells.ThelevelsofAgo2andExp5werefoundtobelowerin
U87-MG cells than in HeLa and T47D cells which had
roughly equivalent amounts of these proteins. TRBP levels
varied somewhat less in the cell lines tested, diﬀering byless
than 2-fold.
To determine if siRNA competition correlated with
diﬀerences in expression of the various RISC proteins, the
activity of Eg5 siRNA was evaluated in the absence or
presence of increasing amounts of PTEN siRNA in HeLa,
T47D and U87-MG cells (Figure 2). Cells were transfected
with Eg5 siRNA at concentrations ranging between 20pM
and 20nM, alone or co-transfected with the PTEN
competitor siRNA at concentrations of 2, 6 or 20nM
for 4h as detailed in ‘Materials and Methods’ section.
Following transfection, cells were incubated overnight
then harvested and total RNA isolated. To detect small
changes in siRNA potency, quantitative RT/PCR was
performed to assess the reduction of Eg5 mRNA. In the
absence of competitor siRNA, the IC50 for siRNA-
mediated reduction of Eg5 was similar in HeLa and
T47D cells (92 18 and 76 15pM, respectively) and
approximately 2-fold higher in U87-MG cells
(198 45pM). In all cell lines, the IC50s for Eg5 inhibition
increased when co-transfected with increasing amounts of
PTEN competitor siRNA. When nonspeciﬁc oligodeox-
ynucleotide carrier was added to the transfections to
equalize the total amount of nucleic acid transfected, the
results were identical eliminating the possibility that the
observed levels of competition might be due to diﬀerences
in transfection eﬃciency (Supplementary Figure 2).
In HeLa cells, competition with PTEN siRNA at the
highest concentration of 20nM (open triangles) resulted in
an increase in the IC50 for Eg5 siRNA to 772 227pM,
approximately 8-fold higher than observed in the absence
of competitor (Figure 2A). Similarly, in T47Ds, competi-
tion with 20nM PTEN siRNA increased the IC50 nearly
7-fold (Figure 2B). In contrast, a similar magnitude of
competition was achieved in U87 cells using only 6nM
PTEN siRNA competitor (circles; IC50=1.2 0.3nM)
and an over 19-fold increase in IC50 was observed in the
presence of 20nM competitor (IC50=3.8 1.5nM,
Figure 2C).
The competitive ability of three other siRNAs targeted
to PTEN was also compared in HeLa and U87 cells
(Supplementary Figure 3). In all cases the amount of
competition observed was higher in U87 than HeLa cells,
conﬁrming that these relationships are not limited to a
single siRNA.
Ago2 levels, butnot Exp5, Diceror TRBP limit siRNA
activity andthe magnitude ofsiRNA competition
The comparatively low levels of Ago2 and Exp5 in U87
cells relative to HeLa and T47D, together with the higher
levels of competition in U87 cells suggested that diﬀer-
ences in the magnitude of siRNA competition between cell
lines may be inversely correlated with Ago2 and/or Exp5
levels. To explore this hypothesis and determine if
reduction in innate levels of RISC components resulted
in changes in siRNA competition and potency, siRNA or
RNaseH-dependent antisense oligonucleotide (ASO) inhi-
bitors of RISC components were employed. The activity
of each agent used to reduce the levels of RISC was ﬁrst
determined in HeLa cells. Cells were transfected with
siRNAs or ASOs at concentrations ranging between 2pM
and 60nM. Following transfection, cells were incubated
overnight, then harvested and total RNA isolated.
Quantitative RT/PCR was performed to assess the
reduction of each targeted mRNA. siRNAs targeting
TRBP and Exp5 were the most potent with IC50s for
target mRNA reduction of 25 5 and 38 9pM,
Dicer
Exp5
tubulin
HeLa U87 T47D
100 546 157
100 113 25
Ago2
TRBP
100 79 142
100 30 83
HeLa U87 T47D
tubulin
Figure 1. Protein levels of RISC components vary between cell lines.
Western blots were prepared from RIPA lysates of HeLa, T47D or
U87-MG cells as detailed in ‘Materials and Methods’ section. RISC
proteins were detected using antibodies speciﬁc for Ago2, Dicer, Exp5
and TRBP proteins. An antibody to tubulin was used as a loading
control and to normalize signals. Data are presented as the average
percent expression for duplicate lanes relative to the levels of each
protein in HeLa cells. Extracts of HeLa cells transfected with plasmids
expressing each of the analyzed proteins were also evaluated by western
analysis to prove the speciﬁcity of each antibody and the molecular
weight of the protein (Supplementary Figure 1).
Nucleic Acids Research, 2007, Vol. 35, No. 19 6601respectively (Figure 3A). The siRNA targeting Dicer was
approximately 2-fold less potent with an IC50 of
67 15pM, while the siRNA targeting Ago2 was 4–6-fold
less potent. This is not surprising as reduction of Ago2 has
previously been shown to attenuate siRNA activity (17,18).
ASO agents targeting RISC components had IC50s in the
1–3nM range (Figure 3B). Since these ASOs work via an
RNAseH mechanism (19), reduction of RISC components
would not be expected to aﬀect their activity and, in fact,
the ASO targeting Ago2 was approximately equipotent to
those targeting TRBP and Exp5.
Initially, the eﬀects of RISC protein reduction on
siRNA potency were evaluated. HeLa cells were treated
with ASOs targeted to TRBP, Ago2, Dicer and Exp5at a
concentration of 50nM. Cells were split 24h after the start
of ASO treatment and seeded in 96-well plates. Cells
were allowed to adhere to the plates for 4h, then
treated with siRNA targeting Eg5 at concentrations
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Figure 2. The magnitude of PTEN and Eg5 siRNA competition varies
between cell lines. Cells were treated at doses from 0.02 to 20nM Eg5
siRNA in the absence or presence of PTEN competitor siRNA at a
dose of 2, 6 or 20nM for 4h. The following day qRT/PCR was
performed to assess the reduction of Eg5 mRNA. Inhibition versus
Concentration curves are shown for Eg5 siRNA-mediated mRNA
reduction in the presence of 0 (ﬁlled square), 2 (ﬁlled triangle),
6 (ﬁlled circle) or 20 (open triangle) nM PTEN siRNA. (A) HeLa cells.
(B) T47D cells. (C) U87-MG cells. Calculated IC50s with standard
errors of the mean for Eg5 mRNA inhibition are shown at the bottom
of the ﬁgure. P-values for IC50s were also computed. Signiﬁcant
diﬀerences (P 0.01) are indicated by  .
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Figure 3. RISC reduction. (A) RISC mRNA reduction by siRNAs.
HeLa cells were treated with siRNAs targeted to Dicer, Ago2, TRBP or
Exp5at concentrations between 1pM and 60nM. After 24h, cells were
harvested and expression of the targeted RNA determined by qRT/
PCR. (B) RISC mRNA reduction by RNAseH-dependent antisense
oligonucleotides as above. All data are normalized to total RNA
present as determined by Ribogreen assay. IC50s (pM) are shown for
each target at the bottom of the ﬁgure.
6602 Nucleic Acids Research, 2007, Vol. 35, No. 19from 0.02 to 20nM. Cells were harvested the following
day, RNA isolated, and Eg5 mRNA levels assessed by
qRT/PCR. Reduction of Dicer, TRBP and Exp5 had no
signiﬁcant eﬀect on Eg5 siRNA potency (Figure 4A)
despite target RNA reduction of greater than 85% (data
not shown). In contrast, Ago2 reduction resulted in an
approximately 30-fold decrease in potency of the Eg5
siRNA. Eﬀects of RISC protein reduction on siRNA
competition were next evaluated. HeLa cells were treated
with siRNAs targeted to Ago2 or Dicer at a dose of 50nM
to ensure maximum target reduction. Twenty-four hours
later, cells were seeded in 96-well plates and IC50s for Eg5
siRNA were assessed in the presence or absence of 10nM
PTEN siRNA competitor. Western blot analysis per-
formed using the remaining cells at the time of Eg5 siRNA
transfection conﬁrmed that both Ago2 and Dicer protein
levels were reduced by greater than 70% with siRNA
treatment (Figure 4B). In control cells (Figure 4C,
Figure 4. Ago2 reduction aﬀects both potency and the magnitude of siRNA competition. (A) Hela cells were seeded in 10 cm dishes, then treated with
ASO’s targeted to TRBP, Ago2, Dicer, and Exp5 in the presence of lipid as detailed in Materials and Methods. Cells were split 24hours after the start
of ASO treatment and seeded in 96-well plates. Cells were allowed to adhere to the plates for 4hours then treated with Eg5 siRNA at concentrations
from 0.02 to 20 nM. Cells were harvested the following day and Eg5 mRNA levels assessed by qRT/PCR and normalized to total RNA as measured
by Ribogreen assay to generate IC50 curves. (B) Levels of Ago2 and Dicer reduction in siRNA treated cells were assessed by Western blot 24hours
after initiation of treatment. The tubulin-normalized percent Ago2 and Dicer protein levels relative to control are shown below each lane. (C) HeLa
cells were treated with siRNAs targeting Ago2 or Dicer. After 24hours cells were seeded in 96 well plates then treated 4 hours later at Eg5 siRNA
doses from 2 pM to 60 nM in the presence or absence of 10 nM PTEN competitor siRNA for 4 hours. The following day inhibition vs. concentration
curves for Eg5 mRNA reduction were generated by qRT/PCR. Eg5 inhibition vs. concentration curves for HeLa cells in the presence (solid line) or
absence (dotted line) of PTEN competitor siRNA. IC50’s (pM) in the presence (m) and absence (g) of competitor siRNA are shown.
Nucleic Acids Research, 2007, Vol. 35, No. 19 6603Control), the IC50 for Eg5 siRNA in the absence of PTEN
competitor was 40 8pM, while in the presence of
competitor the IC50 was determined to be 285 50pM.
Reduction of Dicer (-Dicer) had little eﬀect on the siRNA
activity or competition in HeLa cells with IC50s in the
absence and presence of PTEN competitor of 50 8 and
300 40pM, respectively. In contrast, in cells in which
Ago2 was reduced (-Ago2), there was a signiﬁcant change
in both siRNA potency and competition. The IC50 in the
absence of PTEN competitor was determined to be
241 45pM, while competition with PTEN siRNA in
the same cells resulted in an IC50 of 2.98 0.7nM.
Comparing the Eg5 IC50s in the absence of PTEN
competition, there was a decrease in potency of approxi-
mately 6-fold in the cells treated with Ago2 ASO. In
addition, the magnitude of PTEN competition was
increased in these cells as the IC50 in the presence of
competitor was approximately 12-fold greater than in the
absence of competitor, compared to approximately 7-fold
in HeLa cells with normal Ago2 levels. Therefore, the
magnitude of competition was almost 2-fold greater in
HeLa cells in which Ago2 levels were reduced. It is also
interesting to note that Ago2 reduction in HeLa cells
resulted in a change in siRNA potency and competition
comparable to that observed in U87 cells (compare with
Figure 2C). After reduction of Ago2 with siRNAs or
ASOs, the level of Ago2 protein in HeLa cells appears to
be roughly comparable to the level in untreated U87 cells
(compare Figure 1 and Figure 4B).
In other experiments, Exp5 and TRBP were targeted,
and reduction of these proteins had no eﬀect on siRNA
competition or potency (Supplementary Figure 4). These
experimental results were also conﬁrmed with ASO
inhibitors of RISC to avoid potential artifacts of using
two siRNAs. Ago2 reduction repeatedly and consistently
resulted in decreases in siRNA potency and increases in
competition using either ASOs or siRNAs to eﬀect
reduction of Ago2, while reduction of Dicer, TRBP and
Exp5 had no eﬀect on either parameter.
To further conﬁrm the role of Ago2 levels with siRNA
competition, the eﬀect of Ago2 overexpression on siRNA
competition was evaluated. U87-MG cells were trans-
fected with an Ago2 expression plasmid as detailed in
‘Materials and Methods’ section. The following day,
control and Ago2 overexpressing cells were transfected
with Eg5 siRNA at doses from 2pM to 60nM in the
presence or absence of 5nM PTEN siRNA competitor.
Increased levels of Ago2 expression in plasmid transfected
cells were also conﬁrmed by qRT/PCR. Total RNA was
isolated 24h later and IC50s for Eg5 mRNA reduction
determined by qRT/PCR. In control U87-MG cells, the
IC50 was determined to be 291 79pM while in cells
overexpressing of Ago2, the IC50 was determined to be
65 18pM; a 4–5-fold increase in siRNA potency
(Table 1). The IC50 of the Eg5 siRNA in the presence of
PTEN siRNA increased 5.6-fold in untreated cells and
only 2.1-fold in cells previously transfected with Ago2
plasmid. In other experiments overexpression of Dicer,
Exp5 or TRBP had no eﬀect on the potency of Eg5 siRNA
or competition due to PTEN siRNA (data not shown).
In our system, reduction of Dicer did not aﬀect siRNA
potency. Two reports in which siRNAs were used to
reduce Dicer suggested that it was required for siRNA
activity (17,20), but studies in which the Dicer gene was
knocked out suggested that Dicer was required for
miRNA processing and activity, but not required for
siRNA activity (21,22). To address the possibility that the
levels of Dicer protein reduction in our system were not
suﬃcient to observe an eﬀect on siRNA activity, the eﬀect
of Dicer reduction on the potency of the 19-mer PTEN
siRNA was compared with a 40-mer RNA duplex
targeting the same site. It has been shown RNA duplexes
27 base pairs and greater in length require the presence of
Dicer for cleavage into 21-22 base duplexes capable of
activating RISC (23). HeLa cells were treated with 50nM
ASO targeting either Ago2 or Dicer. Twenty-four hours
later, the cells were seeded in 96-well plates and IC50s for
PTEN siRNA were assessed for the 19-mer or 40-mer
PTEN siRNAs. Reduction of Ago2 and Dicer was also
evaluated by qRT/PCR and found to be greater than 80%
for both genes. While Ago2 reduction resulted in
decreased potency of the 19-mer siRNA, reduction of
Dicer had no eﬀect (Figure 5A). Conversely, both Ago2
and Dicer reduction resulted in a similar decrease in the
potency of the 40-mer siRNA (Figure 5B). To ensure that
these results were not complicated by the activation of the
dsRNA-dependent interferon response (24), treated cells
were also monitored for apoptosis. HeLa cells were either
mock transfected or transfected with 30nM ISIS 138648
to reduce Dicer expression. The following day cells were
treated with either the 19-mer or 40-mer PTEN siRNA at
a concentration of 50nM. Caspase 3/7 levels were then
determined at 18 or 42h posttransfection as detailed in
‘Materials and Methods’ section. Treatment with either
the 19-mer or 40-mer resulted in no increased caspase
levels when compared with untreated cells at any time-
point (data not shown).
To conﬁrm that processing of the 40-mer siRNA
substrate was required for Ago2-mediated activity,
in vitro cleavage reactions were performed with puriﬁed
Ago2. Either PTEN 19-mer or 40-mer siRNA guide
strand was incubated with
32P labeled target RNA in the
presence of recombinant Ago2 as detailed in ‘Materials
and Methods’ section. Cleavage products were resolved by
Table 1. Overexpression of Ago2 in U87-MG cells aﬀects siRNA
potency and competition
Cell line Control Ago2+
10nM PTEN siRNA – + – +
IC50 (pM) 291 79 1640 499 65 18 138 40
Fold change IC50 5.6 2.1
U87-MG cells were transfected with pCMV-Ago2. After 24h Ago2
overexpression was conﬁrmed by western blot and cells were seeded in
96-well plates then treated with Eg5 siRNA at doses from 2pM to
60nM (N=4/dose) in the presence or absence of 10nM PTEN
competitor siRNA for 4h. The following day inhibition versus
concentration curves for Eg5 mRNA reduction were generated by
qRT/PCR. Calculated IC50s with standard error for control and Ago2
overexpressing cells, along with the fold change in IC50 in the presence
of competitor are shown.
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produced a cleavage product of the expected size, no
activity was observed with the 40-mer guide strand
(Figure 5C). Therefore, activity observed for the 40-mer
when transfected into cells must be dependent upon
cleavage by Dicer to a length capable of loading Ago2 and
directing target cleavage. Taken together these data
suggest that while reduction of Dicer is suﬃcient to
aﬀect processing of a 40-base pair substrate, only Ago2
reduction aﬀects the potency of the 19-mer siRNA.
Others have reported that, like Dicer, reduction of
TRBP results in a decrease in siRNA activity (20). Since in
these experiments siRNAs were co-transfected, it is
possible that siRNA competition rather than reduction
of cellular levels of Dicer or TRBP may be responsible for
the reported reduction in siRNA activity. To address this
possibility, IC50s for Eg5 siRNA were determined follow-
ing co-transfection with siRNAs targeting RISC genes at a
concentration of 10nM, rather than waiting 24h between
RISC siRNA and Eg5 siRNA treatment. Under these
conditions Eg5 siRNA potency decreased by 3.5-fold in
the presence of Dicer siRNA and over 15-fold in the
presence of TRBP or Exp5 siRNA (Figure 6A).
To conﬁrm these results, HeLa cells were transfected
with either the TRBP siRNA or an RNAseH-dependent
ASO complementary to the same target. Twenty-four
hours later, the cells were transfected with Eg5 siRNA at
doses ranging from 2pM to 60nM. Cells were harvested
the following day and the IC50s for Eg5 mRNA reduction
determined. The IC50s in cells treated with either the
TRBP ASO or siRNA were not signiﬁcantly diﬀerent than
in cells with no TRBP reduction (Figure 6B). Eg5 siRNA
IC50s were also determined in cells co-transfected with
15nM TRBP ASO or siRNA. Under these conditions,
while the ASO did not have a signiﬁcant eﬀect on the
potency of the Eg5 siRNA, the potency in the presence of
Figure 5. Dicer reduction aﬀects 40-mer, but not 19-mer siRNA activity. (A) 19-mer PTEN siRNA activity was evaluated in control HeLa cells (ﬁlled
square) or in HeLa cells that had been treated 24h previously with ASOs targeting Ago2 (ﬁlled triangle) and Dicer (ﬁlled circle). (B) 40-mer PTEN
siRNA activity in Ago2/Dicer-reduced HeLa cells. (C) Recombinant human Ago2 activity assay. Recombinant Ago2 was incubated with either
PTEN 19-mer or 40-mer siRNA guide strand in cleavage buﬀer and
32P labeled target RNA as detailed in ‘Materials and Methods’ section. Cleavage
products were resolved by denaturing PAGE. Lane 1: 19-mer siRNA guide strand; Lane 2: 40-mer siRNA guide strand.
Nucleic Acids Research, 2007, Vol. 35, No. 19 6605the TRBP siRNA decreased appreciably (Figure 6C).
Results of experiments using Dicer siRNA were similar
(data not shown). These ﬁndings reveal that siRNAs
directed to RISC components can themselves compete to
diﬀerent extents when co-transfected with another siRNA
(reporter), however, competition does not occur if there is
a period of recovery of 24h or less between transfection of
the two siRNAs. When transfected 24h apart, rather than
co-transfected, only Ago2 siRNA had an eﬀect on the
potency of 19–21-mer siRNAs, suggesting that only
reduction of Ago2, but not other RISC proteins, aﬀects
siRNA activity. Furthermore, these data conﬁrm that
DNA-like ASOs work via a pathway that diﬀers from the
RISC pathway and can serve as eﬀective controls for
siRNA mechanistic studies.
Kinetics ofRISC loading andreloading
Since our data suggested that new RISC must become
available for siRNA activity in a period less than 24h we
sought to use siRNA competition to evaluate the kinetics
of RISC loading and reloading. We deﬁne ‘loading’ as the
process between transfection of an siRNA and the
induction of detectable cleavage of the target mRNA.
Obviously the precise time required to load RISC is not
determined. We deﬁne ‘reloading’ as the steps required to
release an siRNA from RISC, acquire a new siRNA, and
cleave the new target mRNA. To evaluate RISC loading
kinetics, Eg5 siRNA activity was measured in the presence
of the PTEN competitor siRNA added simultaneously or
at various times after the initiation of transfection of the
Eg5 siRNA. In the absence of PTEN siRNA competition,
78.3 11.2% reduction of Eg5 message was observed in
cells treated with 300pM Eg5 siRNA, while in the
presence of 10nM PTEN siRNA competitor added
simultaneously only 40.6 11.5% reduction was observed
(Figure 7A). When the addition of PTEN competitor
siRNA was delayed from 5 to 30min no eﬀect on
competition was observed. When addition of PTEN
siRNA was delayed by 60min, the percent reduction of
Eg5 siRNA increased to 65.8 12.5% and by 120min the
percent reduction was comparable to that observed with
Eg5 siRNA treatment alone. These results indicate that
the Eg5 siRNA maximally loaded the RISC available in
the cells in 1–2h. Once RISC was loaded with the Eg5
siRNA, the more potent PTEN siRNA, the guide strand
of which displays higher aﬃnity for puriﬁed Ago2, was
unable to compete, indicating that the association of
siRNA with activated RISC is stable. To exclude the
possibility that diﬀerences in competition are the result of
a decreased ability of the cells to be double transfected
with time, cells were pre-treated for 2h with the
transfection mixture minus siRNA. Cells were then
treated with Eg5 siRNA. As a control, cells were
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Figure 6. RISCsiRNAscancompete forsiRNAactivity,butcompetition
does not occur if transfection of siRNAs are separated by 24h.
(A) HeLa cells were treated at doses from 2pM to 60nM Eg5 siRNA in
theabsenceorpresenceofDicer,TRBPorExp5siRNAatadoseof10nM
for4h.ThefollowingdayqRT/PCRwasperformedtoassessthereduction
of Eg5 mRNA. Inhibition versus concentration curves are shown for Eg5
siRNA-mediated mRNA reduction with no competitor (ﬁlled square),
Dicer siRNA (ﬁlled triangle), TRBP siRNA (ﬁlled circle) or Exp5 siRNA
(opentriangle).(B)HeLacellsweretransfectedwith15nMsiRNAorASO
targeting TRBP. After 24h cells were transfected again with Eg5 siRNA
at doses from 2pM to 60nM for 4h. The following day IC50s for Eg5
mRNA reduction were generated by qRT/PCR. (C) HeLa cells were
co-transfected with 15nM siRNA or ASO targeting TRBP and with Eg5
siRNA at doses from 2pM to 60nM for 4h. The following day IC50s for
Eg5 mRNA reduction were generated by qRT/PCR. Eg5 siRNA
only (ﬁlled square), +TRBP siRNA (ﬁlled triangle), +TRBP ASO
(ﬁlled circle).
6606 Nucleic Acids Research, 2007, Vol. 35, No. 19transfected with the siRNA without lipid pre-treatment.
IC50 curves for Eg5 reduction determined the following
day were virtually super-imposable (Figure 7B) suggesting
that the results of the RISC loading experiments are not
simply a transfection artifact.
To evaluate the reloading of RISC, HeLa cells were pre-
treated for 3h with 15nM PTEN siRNA. Cells were
washed, then 300pM Eg5 siRNA added at times following
PTEN siRNA treatment. Eg5 siRNA transfections were
carried out for 3h, then the cells incubated overnight. The
following day RNA was puriﬁed and the percent reduction
of Eg5 mRNA determined by qRT/PCR. Cells that were
notpre-treatedwithPTEN siRNA(E)showedgreaterthan
65% reduction of Eg5 mRNA (Figure 7C, solid bars).
In contrast, cells pre-treated with PTEN siRNA displayed
approximately 28% reduction of Eg5 mRNA at the same
dose when the Eg5 siRNA was transfected immediately
afterPTENsiRNAtreatment(T=0).After2hthepercent
reductionwasincreasedfrom28%approximately46%and
increasedto55%by9h.After12h,thePTENsiRNAfailed
to attenuate the eﬀects of Eg5 siRNA. To determine if the
loss of competition resulted from unloading of RISC or
because of new synthesis of Ago2, protein synthesis was
inhibited in HeLa cells in similar experiments. When
cycloheximide was added to cells following the PTEN
siRNA pre-treatment, Eg5 mRNA reduction followed the
samepatternasintheabsenceofcycloheximide(Figure7C,
crosshatched bars). In these experiments, S
35 methionine
incorporation was determined to be inhibited by greater
than 95% (data not shown). The similarity of recovery of
Eg5 inhibition in the presence or absence of cycloheximide
suggests that new protein synthesis is not required. Instead,
RISC must in some manner be unloaded and recycled.
Together, these kinetic data indicate that loading of
RISC after transfection is fairly rapid; within 2h of the
initiation of transfection, RISC is loaded and can result in
detectable cleavage of target mRNA. RISC recycling is a
slower process taking as long as 12h to complete.
DISCUSSION
It has previously been observed that co-administration of
two siRNAs can result in inhibition of siRNA activity
(11). The objective of this study is to begin to understand
the molecular mechanisms by which siRNA competition
takes place and to use the competition between siRNAs to
deﬁne basic characteristics of the RISC pathway.
In this study, we demonstrate that the levels of several
protein components of the RISC pathway vary from cell
line to cell line (Figure 1). The potencies of siRNAs also
varied as a function of the cell lines (Figure 2). Moreover,
the extent of competition between siRNAs varied in a
similar fashion to potency. In the competition assay, both
siRNAs were transfected simultaneously, so diﬀerences in
the eﬃciency of transfection cannot account for these
observations. Ago2 and Exp5 are signiﬁcantly less
abundant in U87 cells relative to HeLa and T47D cells.
Only reduction of Ago2 by either a siRNA or by an
RNase H-dependent ASO reduced the potency of Eg5
siRNA (and other siRNAs) and the extent of competition
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Figure 7. Kinetics of RISC loading and reloading. (A) RISC loading.
HeLa cells were treated with Eg5 siRNA at 300pM. 10nM PTEN siRNA
competitorwasaddedbetween0and240minaftertheinitiationoftheEg5
siRNA transfection. Transfections were carried out for a total of 5h. Cells
were harvested the following day and total RNA puriﬁed. The percent
inhibition of Eg5 mRNA is shown at the various timepoints for the
addition of PTEN competitor. E=Eg5 siRNA only, no competitor.
(B) Cells were pre-treated for 2h with the transfection mixture minus
siRNA. Cells were then treated with 2pM to 60nM Eg5 siRNA. As a
control,cellsweretransfectedwiththesiRNAwithoutlipidpre-treatment.
IC50s (pM) for Eg5 reduction determined the following day by qRT/PCR.
Control cells (open square). Lipid pre-treated cells (open triangle).
(C) RISC reloading. HeLa cells were treated for 3h with PTEN
siRNA. Cells were washed then treated with 300pM Eg5 siRNA at
0–18h following the removal of the PTEN siRNA. Transfections were
carried out for 3h. The following day cells were harvested and total
RNA puriﬁed. The percent inhibition of Eg5 mRNA is shown at the
various timepoints following removal of PTEN competitor siRNA. The
experiment was performed in the presence (solid bars) or absence (striped
bars) of 25mg/ml cycloheximide (CHX).
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more than 70% had no eﬀect on either parameter.
To conﬁrm the unique importance of Ago2, we also
overexpressed each of the proteins. Only Ago2 over-
expression resulted in an increase in potency and an
attenuation of competition (Table 1). These results
conﬁrm and extend previously reported observations of
other investigators who demonstrated that Ago2 is an
essential component for siRNA-directed RNA interfer-
ence (6–8,18). Moreover, these observations appear to be
generalizeable as we have studied multiple siRNAs and
several cell lines and the results are consistent (Figures 2
and Supplementary Figure S3). The data from experi-
ments in which we studied three siRNAs designed to bind
to diﬀerent gene targets (Figure 6A) demonstrate that
these observations are not simply due to diﬀerences in the
target RNAs.
Since Dicer was expressed at much higher levels in
T47D than HeLa cells (Figure 1) and since the degree of
competition was very similar in these cell lines (Figure 2),
it is not surprising that reduction of Dicer had no eﬀect on
competition. However, in our system, reduction of Dicer
did not aﬀect siRNA potency and this diﬀers from
previous reports showing siRNA-mediated depletion of
Dicer-diminished RISC-mediated reporter gene silencing
(17). Another study also reported that depletion of Dicer
and TRBP diminished RISC-mediated reporter gene
silencing (20). In both of these studies the authors
observed a decrease in reporter siRNA activity when
Dicer and/or TRBP were targeted with siRNAs. Our
experiments diﬀered from the previously published
experiments in which the siRNAs were co-transfected, so
we hypothesized that the observed reduction in reporter
activity was due to siRNA competition rather than
reduction of cellular levels of Dicer or TRBP. To conﬁrm
this, we evaluated our siRNAs directed to Dicer, TRBP
and Exp5 for competitive ability and found that all were
eﬃcient competitors of Eg5 when co-transfected into
HeLa cells (Figure 6A and C). However, when transfec-
tion of the reporter siRNA (Eg5) was delayed by 24h or
when cells were co-transfected with an ASO inhibitor, we
never observed an eﬀect on siRNA activity (Figures 4B
and 6B). It should also be noted that siRNAs, but not
shRNAs, have been shown to be active in Dicer knockout
ES cells (21) and that Dicer immunodepleted HeLa S100
extracts retain the ability for targeting siRNA-directed
target RNA cleavage (22,25). Our data conﬁrm siRNA
activity independent of Dicer. However, the activity of a
40-mer ‘Dicer-substrate’ siRNA was found to be attenu-
ated by Dicer reduction in HeLa cells (Figure 5)
demonstrating Dicer protein reduction in our system
was suﬃcient to observe an eﬀect on siRNA activity and
suggesting that a 19-21 base siRNA does not require Dicer
to form active RISC.
The lack of an observed eﬀect of Exp5 reduction on
siRNA activity (Supplementary Figure 4) is in agreement
with a previous study demonstrating that Exp5 over-
expression enhances endogenous miRNA activity but not
siRNA activity (26). More recent experiments suggest that
inthepresenceoflowsiRNAconcentrations,Exp5canplay
a role in siRNA activity (27), however we did not see an
eﬀect of Exp5 reduction on siRNA activity or competition
evenatthelowestconcentrationstested.Ourdatatherefore
supportthecurrenttheorythatExp5isprincipallyinvolved
in the nuclear export of miRNAs and shRNAs (28,29).
Using the competition assay, we have demonstrated
that RISC ‘loading’ requires 1–2h following the initiation
of transfection (Figure 7A). Presumably during that time,
the duplex interacts with components of the RISC
pathway and the guide strand is ultimately translocated
to Ago2 and induces cleavage of the target mRNA. For
these experiments RISC loading is deﬁned by the time
when the fragment of the gene ampliﬁed by qRT/PCR is
degraded. For Eg5 mRNA the siRNA target site is located
towards the 50 end of the transcript, while the qRT/PCR
primer-probe set used is located in the 30 UTR. Holen (30)
has shown that some siRNAs leave cleavage fragments
that may indicate a slowed RNAi cleavage complex.
However, we have also employed a primer-probe set
located 50 of the siRNA cleavage site and found that the
kinetics of Eg5 mRNA reduction were identical (data not
shown), so it is likely that the mRNA target is rapidly
degraded following siRNA cleavage.
Addition of the PTEN siRNA more than 2h after the
addition of Eg5 siRNA, resulted in no inhibition of Eg5
RNA cleavage, i.e. PTEN was no longer able to compete
Eg5 siRNA from Ago2. We speculate that this is due to
changes in the proteins to which the siRNA is bound and/
or the nature of the binding interaction of the guide strand
with Ago2. Perhaps the simplest explanation is that once
the target mRNA is recruited to the guide strand loaded
Ago2, the binding is essentially irreversible until the
mRNA is degraded and Ago2 regenerated. Liu et al. (31)
created mutations in the PAZ domain that abolished its
ability to bind siRNAs, then followed the subcellular
localization of Ago2. In contrast to wild-type Ago2, PAZ
domain mutants failed to accumulate in P-bodies,
suggesting that binding to RNA is critical for their
localization there. It is possible that competition does
not take place after mRNA binding due to diﬀerences in
the cellular compartmentalization of free siRNAs and
those associated with Ago2 and target mRNA in P-bodies.
Obviously, other possibilities exist, and much more work
is needed before we can move beyond speculation.
We also used the competition assay to determine the
kinetics of RISC ‘reloading’. We demonstrated that
programmed RISC in HeLa cells reloaded in 9–12h and
that reloading did not require new protein synthesis, i.e.
Ago2 can be recycled (Figure 7C). Why is the process so
slow? RISC assembled in D. melanogaster extracts uses
ATP hydrolysis to accelerate product release (32).
However, it has been demonstrated that puriﬁed Ago2
can engage in only one catalytic round, that product
cleavage is not ATP-dependent, and that product release is
extremely slow or non-existent (9). These data strongly
suggest that a protein other than Ago2 uses the energy of
ATP hydrolysis to facilitate product release in the more
complete RISC formed in vivo. This is similar to the
behavior of Dicer (33). So the simplest explanation for the
unloading kinetics is that product release, facilitated by
other proteins, is extremely slow. Perhaps unloading of
RISC requires degradation of the mRNA and perhaps this
6608 Nucleic Acids Research, 2007, Vol. 35, No. 19canonlyhappen whenappropriate additional nucleasesare
recruitedtothefullyloadedRISCinP-bodies(34).Itisalso
important to remember that, in fact, we are measuring
reloading with Eg5 siRNA. Reloading of RISC with Eg5
siRNA can only happen when the PTEN siRNA has been
degraded or diluted suﬃciently that its concentration is
insuﬃcienttocompetewithEg5siRNA.Clearly,duringthe
process we call reloading, PTEN siRNA is being degraded/
diluted and the rate of that process will also aﬀect the rate
of perceived reloading. In our system, we typically see
siRNA eﬀects lasting approximately 48h (35). We do not
know why RISC reloading appears to be more rapid than
the loss of siRNA eﬀects, however the duration of eﬀect of
an siRNA is a product of the stability of the siRNA, the
stabilityoftheinteractionofthesiRNAwithRISC,andthe
time required to replace the mRNA that has been lost.
Perhaps by 12h, the concentration of the just-transfected
Eg5 siRNA is high enough to out-compete the PTEN
siRNAstillpresentinthecellforavailableRISC.However,
in the absence of the newly transfected siRNA, the PTEN
siRNA continues to reload and exert its eﬀects. Again, this
speculation can only be evaluated with further work.
It has previously been demonstrated that siRNA
competition is related to potency; i.e. highly potent
siRNAs are able to compete with less potent siRNAs,
limiting the ability of siRNAs with lower potency to
mediate mRNA degradation (12). We also observed that
PTEN siRNA is competitively advantaged relative to Eg5
siRNA. When co-administered, the PTEN siRNA consis-
tently led to the degradation of PTEN mRNA and reduced
the degradation of Eg5 mRNA directed by the Eg5
siRNA. However Eg5 siRNA only weakly reduced PTEN
siRNA activity when the siRNAs were co-transfected
(Supplementary Figure 5). Since both siRNAs are blunt-
ended 19-mer duplexes of unmodiﬁed RNA, transfected
simultaneously into the same cells, the competitive
advantage enjoyed by the PTEN siRNA must be due to
itssequencerelativetotheEg5sequence.Weaskedwhether
the basis for diﬀerences between siRNAs lies in the aﬃnity
of the guide strand for Ago2 and found no correlation
(Lima et al, submitted for publication). However, it is
possible that in our system, which uses puriﬁed Ago2
protein, accessory factors are missing that are required to
facilitate Ago2 binding and competition in the cell.
Clearly, this study has implications for both in vitro gene
functionalization and in vivo co-administration of siRNAs.
In vitro experiments in which siRNAs are co-administered
should be interpreted with caution in order to distinguish
the eﬀects of target reduction from siRNA competition.
It has been shown that in vivo Ago2 levels vary between cell
types (36). Therefore it is possible the potencies of siRNAs
in various cells and tissues may vary widely, both because
of diﬀerences in the distribution of siRNAs and the
relative levels of Ago2. Further, there may be signiﬁ-
cant and unpredictable competition between siRNAs if
co-administered in vivo depending on the relative potencies
of the siRNAs used and the tissue targeted.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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